Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).
NCT07473154 · NOT YET RECRUITING · Phase 2
We track 1 ClinicalTrials.gov studies led by Quell Therapeutics Limited. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Quell Therapeutics Limited.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Quell Therapeutics Limited currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Quell Therapeutics Limited conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.